Ligand Pharmaceuticals Inc (LGND) stock
LGNDNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as LGNDZ, LGNXZ, LGNYZ, LGNZZ
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 6/30433% above fair value
$293.81−7.90 (-2.62%)
Close on Nov 17, 2026Market cap $5.88BP/E 128.3Yield –
Ligand Pharmaceuticals ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Ligand Pharmaceuticals's ebitda for the twelve months ending Sep 30, 2026 was $60.49M, up 16.0% year over year. For fiscal 2025 it was $74.78M, up 491.9% from the year before. Over ten years it grew 9.6% a year on average. The highest annual figure on record is $825.44M in fiscal 2019.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $74.78M | +491.9% |
| FY2024 | Dec 31, 2024 | $12.63M | -73.9% |
| FY2023 | Dec 31, 2023 | $48.46M | -11.2% |
| FY2022 | Dec 31, 2022 | $54.57M | -64.8% |
| FY2021 | Dec 31, 2021 | $154.92M | +145.2% |
| FY2020 | Dec 31, 2020 | $63.19M | -92.3% |
| FY2019 | Dec 31, 2019 | $825.44M | +367.6% |
| FY2018 | Dec 31, 2018 | $176.51M | +123.3% |
| FY2017 | Dec 31, 2017 | $79.03M | +43.2% |
| FY2016 | Dec 31, 2016 | $55.18M | +84.2% |
| FY2015 | Dec 31, 2015 | $29.96M | +34.4% |
| FY2014 | Dec 31, 2014 | $22.28M | +26.6% |
| FY2013 | Dec 31, 2013 | $17.61M | +502.9% |
| FY2012 | Dec 31, 2012 | $2.92M | +52.7% |
| FY2011 | Dec 31, 2011 | $1.91M | – |
| FY2010 | Dec 31, 2010 | -$27.09M | – |
| FY2009 | Dec 31, 2009 | -$5.33M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$5.44M | -108.5% |
| Q2 FY2026 | Jun 30, 2026 | $16.81M | -0.9% |
| Q1 FY2026 | Mar 31, 2026 | $25.58M | – |
| Q4 FY2025 | Dec 31, 2025 | $23.53M | – |
| Q3 FY2025 | Sep 30, 2025 | $63.66M | +424.5% |
| Q2 FY2025 | Jun 30, 2025 | $16.97M | – |
| Q1 FY2025 | Mar 31, 2025 | -$27.45M | -333.5% |
| Q4 FY2024 | Dec 31, 2024 | -$1.01M | -118.2% |
| Q3 FY2024 | Sep 30, 2024 | $12.14M | +3.8% |
| Q2 FY2024 | Jun 30, 2024 | -$10.25M | -236.4% |
| Q1 FY2024 | Mar 31, 2024 | $11.75M | -50.4% |
| Q4 FY2023 | Dec 31, 2023 | $5.56M | – |
| Q3 FY2023 | Sep 30, 2023 | $11.69M | -54.7% |
| Q2 FY2023 | Jun 30, 2023 | $7.51M | -65.7% |
| Q1 FY2023 | Mar 31, 2023 | $23.70M | +50.1% |
| Q4 FY2022 | Dec 31, 2022 | -$8.96M | -117.6% |
| Q3 FY2022 | Sep 30, 2022 | $25.82M | -9.2% |
| Q2 FY2022 | Jun 30, 2022 | $21.93M | -62.4% |
| Q1 FY2022 | Mar 31, 2022 | $15.79M | -8.6% |
| Q4 FY2021 | Dec 31, 2021 | $50.86M | +41.6% |
| Q3 FY2021 | Sep 30, 2021 | $28.43M | +233.6% |
| Q2 FY2021 | Jun 30, 2021 | $58.35M | +405.4% |
| Q1 FY2021 | Mar 31, 2021 | $17.28M | +139.7% |
| Q4 FY2020 | Dec 31, 2020 | $35.91M | – |
| Q3 FY2020 | Sep 30, 2020 | $8.52M | – |
| Q2 FY2020 | Jun 30, 2020 | $11.55M | – |
| Q1 FY2020 | Mar 31, 2020 | $7.21M | -99.1% |
| Q4 FY2019 | Dec 31, 2019 | -$3.47M | -110.0% |
| Q3 FY2019 | Sep 30, 2019 | -$1.21M | -104.2% |
| Q2 FY2019 | Jun 30, 2019 | -$272.00K | -100.4% |
| Q1 FY2019 | Mar 31, 2019 | $830.38M | +1973.7% |
| Q4 FY2018 | Dec 31, 2018 | $34.51M | +8.8% |
| Q3 FY2018 | Sep 30, 2018 | $28.77M | +55.4% |
| Q2 FY2018 | Jun 30, 2018 | $73.19M | +369.1% |
| Q1 FY2018 | Mar 31, 2018 | $40.04M | +203.5% |
| Q4 FY2017 | Dec 31, 2017 | $31.72M | +42.1% |
| Q3 FY2017 | Sep 30, 2017 | $18.51M | – |
| Q2 FY2017 | Jun 30, 2017 | $15.60M | – |
| Q1 FY2017 | Mar 31, 2017 | $13.20M | – |
| Q4 FY2016 | Dec 31, 2016 | $22.32M | – |
See a number that looks wrong?